Antiviral treatment for chronic hepatitis B by Wu, PC & Lai, CL
Title Antiviral treatment for chronic hepatitis B
Author(s) Lai, CL; Wu, PC
Citation Hong Kong Medical Journal, 1997, v. 3 n. 3, p. 289-296
Issued Date 1997
URL http://hdl.handle.net/10722/53408
Rights Creative Commons: Attribution 3.0 Hong Kong License
HKMJ Vol 3 No 3 September 1997      289
Chronic hepatitis B
Department of Medicine, Queen Mary Hospital, Pokfulam, Hong
Kong
CL Lai, MD, FRCP
Department of Pathology, The University of Hong Kong, Pokfulam,
Hong Kong
PC Wu, MD, FRCPath
Correspondence to: Prof CL Lai
Antiviral treatment for chronic hepatitis B
CL Lai, PC Wu
An updated review of the antiviral agents currently available or under trial for the treatment of chronic
hepatitis B is presented. There are two broad groups: (1) immunomodulators including interferon α
(which also has a direct antiviral effect), thymosin α1 and Theradigm-HBV and (2) viral suppressors
such as famciclovir and lamivudine. These agents are still in clinical trial worldwide, singly or in
combination. Their long term efficacy in the treatment of hepatitis B remains to be evaluated.
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Introduction
It is estimated that as many as 25% to 40% of the 300
to 350 million hepatitis B surface antigen (HBsAg)
carriers in the world will eventually die from cirrhosis
of the liver and/or hepatocellular carcinoma (HCC).1
Since there is a progressive increase in the incidence
of HCC with age, it has been suggested that all HBsAg
carriers will eventually die from HCC and/or cirrhosis
if they live long enough.2
The ultimate aim in the treatment of HBsAg carriers
is therefore to decrease, or prevent altogether, the
development of cirrhosis and HCC. This requires
decades of follow up of treated patients. More realistic
short term objectives (usually used in clinical trials)
include the following: (1) viral suppression, which is
established by the disappearance of serum hepatitis B
virus (HBV) DNA (using hybridization assay) and
hepatitis Be antigen (HBeAg) with or without antibody
against HBeAg (anti-HBe); (2) decreased liver damage,
established by the normalisation of serum transaminase
levels (if these were previously elevated) and improved
liver histology; and (3) complete eradication of HBV,
this is indicated by the loss of HBsAg and detectable
HBV DNA in the serum and liver, even by polymerase
chain reaction (PCR) assay or branch DNA chemi-
luminescent amplification technique. This last
objective is seldom achieved with the current treatment
regimens.
The agents currently used or under trial for the
treatment of chronic hepatitis B can be broadly
separated into two groups (Table 1). The first group
are the immunomodulators, which act by modulating
the immune response of the host to the HBV antigens
that are expressed on the surface of the hepatocytes.3
The main mode of action of interferon alpha (IFNα)
in HBsAg carriers is immunomodulation, but it also
has a direct antiviral effect. Other newer immuno-
modulators include thymosin α1 (Tα1) and therapeutic
vaccines, such as Theradigm-HBV (Cytel, San Diego,
Ca, US). The second group of agents comprises viral
suppressors. The most promising agents in this group
are famciclovir and lamivudine (Glaxo Wellcome,
London, UK).
Interferon alpha
This is currently the only agent approved for use in
the treatment of HBsAg carriers. It is given sub-
cutaneously at a dose of 5 mU daily or 10 mU thrice
weekly for 16 weeks. A meta-analysis of 15 ran-
domised placebo-controlled studies showed that IFNα
Table 1. Agents currently used or under trial for
treating chronic hepatitis B
Immunomodulators
Interferon α
Thymosin α1
Therapeutic vaccines, eg, Theradigm-HBV
Viral suppressors
Famciclovir
Lamivudine
Ganciclovir
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was beneficial (Table 2).4 Its usefulness, however, is
limited. Loss of HBeAg and HBV DNA occurred only
20% more frequently in treated patients than in control
patients and loss of HBsAg occurred in only 6% more
patients. Interferon alpha had a significant effect on
the normalisation of alanine aminotransferase (ALT)
levels. Most studies have demonstrated that
successfully treated patients have liver biopsies that
histologically, show less evidence of damage.
When the cost-effectiveness of IFNα treatment was
calculated based on the meta-analysis of nine random-
ised trials,5 it was concluded that for a 35-year-old
individual with HBeAg-positive chronic hepatitis B,
IFNα increases life expectancy by only 3.1 years or
3.4 quality-adjusted life-years. This modest increase
in life expectancy was, however, based on certain
questionable assumptions. The authors calculated that
patients who are HBeAg-positive and HBsAg-positive
have a 12.1% probability of developing compensated
cirrhosis annually; whereas patients who are HBeAg-
negative and HBsAg-positive have only a 1.0%
probability of developing the condition. It is now
generally accepted that cirrhosis develops as a result
of the immunological injury to the liver that occurs
during the viral clearance phase when a patient is
seroconverting from HBeAg positivity to anti-HBe
positivity.6-8 The assumption therefore that HBeAg-
negative patients are much less likely to develop
cirrhosis compared to HBeAg-positive patients seems
questionable.
Interferon alpha treatment combined with
steroid priming
Steroid therapy in a chronic hepatitis B patient causes
enhanced viral replication,9 possibly acting through
the glucocorticoid-responsive element in the HBV
genome.10 Following withdrawal of a short course of
steroid, there is a decline in HBV DNA and HBV
DNA polymerase levels that coincides with an im-
munological rebound with enhanced T lymphocyte
function.11 This improved T lymphocyte function may
potentiate the effect of interferon. A large multicentre
trial, however, has shown an almost identical rate of
HBeAg seroconversion in patients treated with
IFNα alone and in patients pre-treated with steroid
followed by IFNα.12 Moreover, steroid withdrawal is
documented to precipitate hepatic decompensation (as
a result of hepatocyte necrosis) in patients with
marginal liver function, which can be fatal in some
cases.13-15 Such fatal reactivation on withdrawal of
steroid can sometimes occur in completely asympto-
matic HBsAg carriers16 and steroid should therefore
be used with caution in HBsAg carriers. Withdrawal
of steroid is not recommended as a routine procedure
prior to a course of IFNα.
Response of Oriental hepatitis B carriers to
interferon alpha
At least 50% of Oriental HBsAg carriers acquire the
infection perinatally,17 and a large proportion of the
remainder acquire the infection within the first few
years of life.18 Such early infection is believed to induce
immune tolerance to HBV, possibly through deletion
of T cells that can recognise HBeAg and the hepatitis
B core antigen (HBcAg).
Two large scale trials have been carried out in adult
Chinese HBsAg carriers in Hong Kong.19,20 The results
of the second trial are summarised in Table 3. In this
study, the carriers were randomised into those who
had normal pre-treatment ALT levels and those with
persistently elevated pre-treatment ALT levels (raised
for more than three consecutive months). Interferon
alpha had little effect in patients with normal ALT
levels, while the response to IFNα, with or without
prednisone priming, was slightly better in patients with
elevated ALT levels. The elevated ALT in these
patients, however, also suggests that they were in the
viral clearance phase. The spontaneous seroconversion
rate to HBeAg positivity in the control group was as
high as 19% within one year. Hence, the authors
concluded that even in patients with elevated ALT
levels, “it is not clear whether interferon merely
Table 2. Summary of the results of a meta-analysis of 15 randomised placebo-controlled trials of
interferon alpha in chronic hepatitis B4
IFNα* treated group (%) Control group (%) P value
Loss of HBV DNA 37 17 P<0.0001
Loss of HBeAg 33 12 P<0.0001
Loss of HBsAg 7.8 1.8 P<0.001
*IFNα    interferon alpha
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hastened the process of endogenous inhibition of
HBV replication or provided actual benefit to some
patients.”20
Two randomised trials have also been carried out
in Chinese children who are hepatitis B carriers.21,22
However, the results have been equally disappointing.
Hence, the poor response seen in adult carriers does
not appear to be related to delayed treatment of the
disease.
Effect of interferon alpha in producing viral
eradication
A meta-analysis of 15 randomised trials has shown
that loss of HBsAg positivity occurred 6% more often
in IFNα-treated patients than it did in control patients,
six months after treatment ceased.4 On long term follow
up, 65% of IFNα-treated Caucasian patients who have
had a sustained loss of HBeAg also lose HBsAg.23
However, only 24% of Spanish responders and none
of the Chinese responders lost HBsAg on long term
follow up.24,25 Complete disappearance of HBV DNA
as tested by PCR assay, occurs only rarely in IFNα-
treated patients who clear HBeAg but remain positive
for HBsAg. Of the 272 Chinese adult and child HBsAg
carriers who participated in three randomised placebo-
controlled trials, 5.9% of the treated patients and 1.2%
of the control patients became HBV DNA negative on
long term follow up, a statistically insignificant result.26
Adverse effects of interferon alpha
The adverse effects of IFNα are dose-related and can
be severe (Table 4). Although most adverse effects can
be decreased by reducing the dosage of IFNα, some
can lead to the premature ending of therapy. The
initial influenza-like syndrome can be minimised by
gradually increasing the dose. The induction of auto-
antibodies, although usually clinically silent, can lead
to overt hypo- and hyper-thyroidism and idiopathic
thrombocytopenic purpura.27 Interferon therapy may
also induce autoimmune hepatitis in individuals
who are genetically predisposed to developing auto-
immune liver disease.28,29 The presence of interferon
neutralising antibodies is often of no clinical im-
portance, but when present in large amounts, they can
counteract the effects of IFNα. In patients with
advanced hepatitis, IFNα may worsen liver function.
It also increases susceptibility to bacterial infection,
and should therefore be used only under close
monitoring in patients with mild or moderate hepatic
decompensation.
Thymosin alpha 1
This is an immunomodulator that has several modes
of action; it primarily increases the efficiency of T
cell maturation.30 It also acts on T cells after maturation,
increasing the production of cytokines such as
interferon γ and interleukin 2,31 and it upregulates
the expression of cytokine receptors.32 A study of
Table 3. Summary of the response to interferon alpha treatment in Chinese adult HBsAg carriers20
Prednisone IFNα Control P
+ IFNα* (%) alone (%) group (%) value
Patients with elevated ALT
   loss of HBeAg 43 33 19 ns
   loss of HBsAg 0 6 0 ns
Patients with normal ALT
   loss of HBeAg 0 10 0 ns
   loss of HBsAg 0 5 0 ns
ns    not significant
*IFNα    interferon alpha
Table 4. Adverse effects of interferon alpha
Influenza-like syndrome (rapid tachyphylaxis)
Myalgia
Marrow suppression (usually moderate)
Alopecia
Depression (occasionally severe)
Autoantibody induction
Induction of interferon-neutralising antibodies
In patients with advanced hepatitis/cirrhosis
- susceptibility to bacterial infections
- liver function deterioration
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woodchuck hepatitis virus-infected woodchucks
treated with Tα1 seems promising.33
In a phase II trial involving patients with chronic
hepatitis B, seven patients received Tα1 while five patients
received subcutaneous placebo injections twice weekly
for six months.34 More of the thymosin-treated patients
cleared HBV DNA from their sera, and had an absence
of replicative forms of HBV DNA in their liver biopsies,
compared with patients in the control group (P<0.04). A
response to thymosin therapy was associated with
improved peripheral lymphocyte, CD3, and CD4 counts,
and in interferon γ production. The serological improve-
ments were sustained during follow up.
In an American Phase II, multicentre, randomised,
controlled trial involving 99 patients, the preliminary
results suggest a trend in favour of Tα1 compared
with placebo, but the results are far less promising
than those of the phase II trial.35 Other phase III trials
are being performed in Taiwan and Singapore. Any
definitive conclusions concerning the usefulness of
Tα1 must await the final outcome of these phase III
trials.
The effect of combining Tα1 with lymphoblastoid
IFN has been tested in 15 patients. Preliminary data
show a loss of HBV DNA in 60% of patients and a
loss of HBsAg in 40%.36 Again, firm conclusions have
to await the results of further trials. As to the safety of
Tα1, no adverse events have been reported to date in
the more than 1000 subjects who have been treated
with the drug.
Therapeutic vaccines
Patients who clear HBV develop a strong HLA class
I-restricted response; this response is weak in HBsAg
carriers. Both withdrawal of steroid and IFNα probably
act by inducing cytotoxic T lymphocytes (CTL).
A therapeutic vaccine, Theradigm-HBV, has been
designed to induce a CTL response to HBV.37 Theradigm-
HBV has three components: the HBcAg peptide 18-
27, and two additional components for enhancing
immunogenicity, i.e. tetanus toxoid peptide 830-843.
The HBcAg peptide 18-27 was selected because it has
been shown to be recognised by CTL from patients
with acute HBV infection.38,39
A dose escalation trial in 26 normal subjects showed
that Theradigm-HBV is safe to use. It induces a primary
HBV-specific CTL response with the first dose and a
booster effect with the second dose, given 28 to 35
days later. A phase II study is underway to determine
the efficacy of vaccinating HBsAg carriers with two
doses of Theradigm-HBV.
Famciclovir
Famciclovir is the oral derivative of penciclovir. It is
converted to penciclovir in the intestinal wall and in
the liver after absorption.40 Penciclovir is a guanine
analogue that inhibits viral DNA chain elongation by
competing for viral DNA polymerase in its active
intracellular triphosphate form.41 It has a potent effect
on herpes simplex and zoster viruses.42
Famciclovir suppresses the replication of the
duck hepatitis B virus in the Pekin duck and human
HBV replication in human hepatoma cells transfected
with the HBV genome.43 In a double-blind placebo-
controlled pilot study, 17 patients were randomised to
receive famciclovir 250 mg three times daily, or 500
mg three times daily, or placebo.44 Of the 11 evaluable
patients who received famciclovir, six showed a greater
than 90% reduction in their HBV DNA level compared
with no reduction in the patients who received placebo.
In four of the responders, the fall in HBV DNA was
sustained throughout the 10-day treatment, and in
two of these, the fall persisted for a further two weeks.
More prolonged courses of famciclovir are now being
assessed for its effect on HBV replication.
Famciclovir has been found to be remarkably safe
in patients with herpes zoster and genital herpes.42 The
most common adverse effects of headache, nausea, and
diarrhoea occur with equal frequency in patients
receiving famciclovir and those receiving placebo.
Lamivudine
Lamivudine [the (-) enantiomer of 2´ deoxy-3´-
thiacytidine] is a 2´3´ dideoxynucleoside similar in
structure to 3´-deoxy-3´-azidothymidine (AZT), 2´3-
dideoxycytidine (ddC), and 2´3-dideoxyinosine (ddI),
drugs used for the treatment of patients with human
immunodeficiency virus (HIV) infection. These agents
inhibit DNA synthesis by causing chain termination
of the nascent proviral DNA in addition to interfering
with the reverse transcriptase activity of HIV and HBV.
Lamivudine was approved for use in HIV patients in
late 1995 because of its synergistic effect with AZT.45
Lamivudine inhibits the replication of HBV in human
HBV-transfected cell lines46 but replicative HBV
DNA reappears when it is withdrawn.47 It is also very
effective in vivo when given to infected ducks and
chimpanzees.
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Multiple phase II dose-ranging trials with or without
placebo have been performed in both Caucasian and
Oriental HBsAg carriers.48-50 Oral daily doses of 5 mg
to 600 mg were given for 4 to 12 weeks. The results of
these trials are essentially identical; HBV DNA
dropped to very low levels within one week of therapy.
The suppression of HBV DNA was suboptimal with
daily 25 mg or smaller doses, but 100% of patients
receiving 100 mg or greater doses daily had almost
complete suppression of HBV DNA (95% to 100%
of pre-treatment levels). There were decreases in
HBeAg and HBsAg titres (Glaxo, unpublished data)
and normalisation of ALT levels.49 These occurred
irrespective of the pre-treatment HBV DNA and ALT
levels in both Caucasians and Orientals.48,49 In the
majority of patients, HBV DNA, HBeAg, and HBsAg,
returned to pre-treatment levels 4 to 8 weeks after
treatment. In 19% of the patients who were given
lamivudine for 12 weeks, however, HBV DNA sup-
pression was sustained.49 The HBeAg disappeared in
12% of patients.
Several large scale multicentre controlled trials are
now being performed in Southeast Asia, Europe, and
the United States, comparing lamivudine with or
without IFN, and with placebo. Since the phase II trials
show that the majority of patients have a rebound of
the HBV DNA on cessation of therapy, lamivudine
probably has to be given on a long term basis.
Suppression of viral replication per se may not be
sufficient; there must be a corresponding decline in
the number of productively infected hepatocytes.50
Reduction in the number of infected hepatocytes
depends on the spontaneous death of infected
hepatocytes and probably also on the inefficient
passage of covalently-closed circular DNA (ccc DNA)
of HBV from infected hepatocytes that proliferate to
replace dying cells.51 Viral suppressors may therefore
have to be administered over many months, if not years.
Patient compliance with oral lamivudine taken once
daily should be good. One conceivable endpoint for
the cessation of therapy would be the complete
eradication of HBV, i.e. the disappearance of HBsAg
and HBV DNA from the serum and liver, as tested by
PCR assay.
It is potentially dangerous to stop lamivudine
prematurely. One report describes a rise in ALT that
occurred in a patient four weeks after discontinuing
lamivudine.52 This rose to 100 times the upper limit of
normal four months later, with the appearance of
jaundice; a liver biopsy showed necrosis of hepato-
cytes. The authors postulate that a reinfection of
hepatocytes occurred after the lamivudine was with-
drawn, followed by a severe immune reaction, as if
the patient were experiencing an acute hepatitis B
episode. The patient survived, with clearance of HBV
DNA and HBeAg after a course of prednisone. The
authors documented that such a rise of ALT occurs in
16% of patients within 8 to 24 weeks of the stopping
of lamivudine treatment. This report supports that
lamivudine may have to be maintained on a long
term basis until there is evidence of complete viral
eradication.
Lamivudine is otherwise a remarkably safe drug,
unlike fialuridine, an investigational drug that caused
severe hepatic failure and lactic acidosis in seven of
15 patients, five of whom died.53 The toxicity of
fialuridine is probably related to its free 3´-hydroxyl
group that allows its incorporation into DNA, including
mitochondrial DNA, at internucleotide linkages.54
Lamivudine lacks this free 3´-hydroxyl group.
Compared with other non-fialuridine nucleoside
analogues, lamivudine also has fewer potential side
effects. Drugs like AZT can cause myopathy and
marrow hypoplasia.55,56 It has been shown in rats that
AZT (which is not incorporated into mitochondrial
DNA) inhibits mitochondrial DNA, RNA, and poly-
peptide synthesis.55 In contrast, lamivudine, when
tested in cell cultures, has much less effect on mito-
chondrial DNA content and on the activity of DNA
polymerase γ, the enzyme responsible for the
replication of mitochondrial DNA.43
The adverse events that have been encountered
with lamivudine in clinical settings are summarised
in Table 5. These events were reported for a total of
19 520 patients, of whom 631 had HBV infection and
18 889 had HIV infection. A large proportion of the
latter patients had been receiving lamivudine for more
than two years.
The haematological abnormalities include mild
anaemia, neutropenia, and thrombocytopenia. A
haematogical abnormality was reported in only one
patient with HBV infection, and that patient had a
liver transplant. Neurological events were mostly in
the form of muscle weakness. Some patients developed
elevations of creatine kinase levels but most of these
patients were symptom-free.
Pancreatitis has so far been reported only in patients
with HIV infection. Approximately one third of the
patients who developed pancreatitis had had
pancreatitis prior to lamivudine treatment. It was often
difficult to decide whether the pancreatitis was causally
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related to lamivudine, a complication of HIV infection,
or whether it was due to concomitant drug treatment
(e.g. steroids and AZT).
Other hepatobiliary complications included
elevated transaminase (not related to withdrawal of
lamivudine), bilirubin, lipase, and amylase levels.
These patients were mostly symptom-free. A small
proportion of patients had diarrhoea, nausea, hypo-
glycaemia, and myalgia. In all, only 1.6% of patients
were reported as having complications, most of which
were mild. Lamivudine is a safe drug to use in patients
with chronic hepatitis B.
Viral suppressors in liver transplantation
Hepatitis B immune globulin (HBIG) is the only
agent proven to be of use for the prevention of HBV
recurrence after liver transplantation for end-stage
hepatitis B cirrhosis. In a study of 372 HBsAg-positive
patients by Samuel and colleagues,57 the three-year
actuarial risk of recurrence of HBV infection was 83%
for HBV DNA-positive patients, 66% for HBV DNA-
negative, HBeAg-positive patients, and 58% for
patients negative for both HBV DNA and HBeAg.
With long term administration of HBIG, the three-year
risk of recurrence was significantly reduced (P<0.001)
but was still 36%. The dosing of HBIG is difficult, as
it requires constant monitoring of anti-HBs titres. Its
cost is also considerable and is estimated to be
US$30 000 per year per patient.
Recently, more encouraging results have been
achieved with the three viral suppressors, ganciclovir,
famciclovir, and lamivudine. The first two agents have
been given to patients who had recurrent HBV
infection despite HBIG treatment. In one series,
ganciclovir was given intravenously to eight of these
patients (and to one patient with de novo HBV
infection) for three to 10 months.58 In all patients,
serum HBV DNA levels fell (mean decrease = 90%).
The ALT levels also decreased. Hepatic expression of
HBV antigens and HBV DNA was reduced in three
of six patients assessed. After discontinuation of
ganciclovir, HBV DNA rebounded in all patients with
the exception of the patient with de novo infection.
Four patients underwent re-treatment with success.
Kruger et al used famciclovir (given orally) in
38 patients with HBV re-infection following liver
transplantation.59 There was a reduction in serum HBV
DNA (median 91% decrease) in 83% of evaluable
patients. Eight patients were given famciclovir for
more than one year without significant side effects.
Lamivudine has been used as a prophylactic
agent to prevent hepatitis B re-infection following
liver transplantation. It is given orally as a single
agent, without HBIG, for at least four weeks prior
to transplantation. In one of the first published
abstracts, 12 patients were transplanted, with one
early post-operative death.60 Before transplantation,
all patients were found positive for HBV DNA by
PCR assay. After transplantation, only one patient
had recurrent HBV infection. The 10 surviving
patients all became negative for serum HBV DNA
and for HBsAg and HBcAg in the liver biopsies.
Six of these patients also lost HBsAg. The drug was
well tolerated except in one patient who developed
sensorimotor neuropathy and myopathy.
Table 5. Adverse events related to lamivudine consumption observed in 19 520 patients*
No. of patients with No. of patients with % of total
HIV infection HBV infection patient population
No. of patients 18 889 631
Nature of adverse events encountered
Haematological 103 1 0.53
Neurological 54 0 0.28
Pancreatic 52 0 0.27
Other hepatobiliary complications 23 5 0.14
Gastrointestinal 39 0 0.20
Endocrineal 26 2 0.14
Musculoskeletal 8 1 0.05
Psychiatric 3 - 0.02
*Data kindly supplied by Glaxo Research and Development Ltd.
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Viral suppressors thus appear to provide an effective
alternative to HBIG in the prevention and treatment of
HBV re-infection after liver transplantation in HBsAg-
positive subjects.
Conclusion
For the treatment of chronic hepatitis B, IFNα is only
of limited use, especially in Oriental populations.
Newer immunomodulators such as Tα1 and therapeutic
vaccines are being assessed clinically. So far, Tα1
appears to generate only a modest effect.
Several viral suppressors of HBV replication have
been assessed. Of these, lamivudine has proved to be
the most potent. However, viral suppressors probably
need to be taken on a long term basis to achieve an
effective decline in the number of productively infected
hepatocytes.
Viral suppressors have also been found to be useful
in the treatment and prevention of recurrence of HBV
after liver transplantation for end-stage hepatitis B liver
disease. When given before liver transplantation, a
significant proportion of patients become HBsAg-
negative after the transplantation.
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